1. Home
  2. SEER vs NKTX Comparison

SEER vs NKTX Comparison

Compare SEER & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.90

Market Cap

106.0M

Sector

Health Care

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$1.84

Market Cap

126.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEER
NKTX
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.0M
126.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SEER
NKTX
Price
$1.90
$1.84
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$13.25
AVG Volume (30 Days)
154.7K
664.0K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,376,999.00
N/A
Revenue This Year
$25.97
N/A
Revenue Next Year
$24.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.11
N/A
52 Week Low
$1.62
$1.31
52 Week High
$2.59
$2.85

Technical Indicators

Market Signals
Indicator
SEER
NKTX
Relative Strength Index (RSI) 35.38 44.97
Support Level $1.91 $1.77
Resistance Level $2.02 $1.93
Average True Range (ATR) 0.08 0.08
MACD -0.00 0.01
Stochastic Oscillator 31.83 60.87

Price Performance

Historical Comparison
SEER
NKTX

About SEER Seer Inc.

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: